April 30, 2025
| Today’s news and insights for biopharma leaders
The company has predicted that Imaavy — now approved for myasthenia gravis — could eventually earn more than $5 billion in annual sales at its peak.
|
The pharma will pay $800 million for the biotech, which was launched nearly two decades ago by Alnylam and Ionis to advance microRNA technology.
|
In its first full quarter, Attruby made more headway than analysts anticipated in its competition with Pfizer’s market-leading drug.
|
Pharmaceutical companies are turning to integrated RWD approaches to overcome challenges in rare disease research.
|
Trium Capital is the latest firm to push a biotech “zombie” to shut down, claiming in a regulatory filing there is more upside to a liquidation than Acelyrin’s planned merger.
|
The company’s CEO said he’s had “productive discussions” with Trump administration officials on a recently launched trade probe.
|
|
Amidst an industry-wide shift to digital solutions, GenAI is helping biopharma leaders create a frictionless contact center and deliver personalized experiences. Learn more in this playbook.
|
|
From Our Library
Webinar - on demand
Custom content for Premier Applied Sciences
|
Playbook
Custom content for MRN
|
Infographic
Custom content for UBC
|
Infographic
Custom content for Reverba Global
|
| 
